Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 8/20 | 0.80 |
| ▸ | BRAF | P15056 | 11/20 | 0.61 |
| ▸ | EGFR | P00533 | 9/20 | 0.59 |
| ▸ | CSF1R | P07333 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588975 | 0.89 | KIT (1.00) | KITBRAFEGFRCSF1R | |
| SCHEMBL29493482 | 0.89 | KIT (1.00) | KITBRAFEGFRCSF1R | |
| SCHEMBL30080656 | 0.89 | KIT (1.00) | KITBRAFEGFRCSF1R | |
| SCHEMBL588917 | 0.89 | KIT (0.93) | KITBRAFEGFRCSF1R | |
| SCHEMBL14704587 | 0.82 | KIT (0.63) | KITBRAFEGFRCSF1R | |
| SCHEMBL590507 | 0.82 | KIT (0.86) | KITBRAFEGFR | |
| SCHEMBL17537391 | 0.82 | KIT (0.80) | KITBRAFEGFRCSF1R | |
| SCHEMBL16755287 | 0.82 | KIT (0.80) | KITBRAFEGFR | |
| SCHEMBL29674969 | 0.82 | KIT (0.80) | KITBRAFEGFR | |
| SCHEMBL31173111 | 0.81 | BRAF (0.71) | KITBRAFEGFRCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2665709-B1 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | SUN PHARMA ADVANCED RES CO LTD (IN) | 2016-12-07 | — | — | EP | disclosed |
| US-9024021-B2 | Diarylacetylene hydrazide containing tyrosine kinase inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2015-05-05 | — | — | US | disclosed |
| EP-2665709-A1 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | Sun Pharma Advanced Research Company Limited (IN) | 2013-11-27 | — | — | EP | disclosed |
| US-20130296557-A1 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2013-11-07 | — | — | US | disclosed |
| WO-2012098416-A1 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296557-A1 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | ABL1, LCK, JAK2 | KIT 214/4885BRAF 81/4885EGFR 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.